A fluid connector is provided. The fluid connector can include a first connector having a first passageway and a second passageway; and a second connector having a third passageway and a fourth passageway. The first connector can be attracted to the second connector through a magnetic force, thereby forming the fluid connector. Moreover, when the first connector abuts the second connector, the first passageway together with the third passageway can form a first fluid path, and the second passageway together with the fourth passageway can form a second fluid path that is different from the first fluid path.
A converterless method for converting 226Ra to 225Ac by direct electron beam bombardment with high energy electron beam having an average effective beam power of about 20 to about 250 kW at a beam energy of about 25 to about 100 MeV to impact the 226BremsstrahlungBremsstrahlung photons, but rather into the production of virtual photons that transmute the target 226Ra to 225Ra that decays to 225Ac.
G21G 1/04 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators
G21G 1/10 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators by bombardment with electrically-charged particles
G21K 5/04 - Irradiation devices with beam-forming means
G21K 5/08 - Holders for targets or for objects to be irradiated
A target for heavy ion or electron bombardment is contemplated as is a method of its preparation. In that method, a) liquid target solution of a target metal salt dissolved in water is deposited into the bottom of a metal target capsule having an open top, and b) heated within the target capsule to form a crystalline material. Steps a) and b) are repeated until the crystalline material contains a target amount of target salt. The target capsule is then heated until the weight of the target capsule remains constant. To mitigate the formation of salt creep during the preparation, the liquid target solution can contain about 2 to about 20 percent v/v of a C2-C4 polyol, or the inside surface of the target capsule is coated with a hydrophobic film that provides a contact angle with water of about 70 to about 1300 prior to liquid deposition.
G21G 1/10 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators by bombardment with electrically-charged particles
4.
LIQUID DEPOSITION OF SALTS FOR BOMBARDMENT TARGET PREPARATION
244 polyol, or the inside surface of the target capsule is coated with a hydrophobic film that provides a contact angle with water of about 70 to about 130° prior to liquid deposition.
C23C 14/22 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the process of coating
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
A cartridge loader is provided. The cartridge loader can include a loader body, a top loader bay slidingly engaged to the loader body, and a bottom loader bay slidingly engaged to the loader body. The cartridge loader can further include a cleaning assembly coupled to the loader body. The cartridge loader can be manipulated from a first configuration to a second configuration, such that when in the first configuration, the cartridge loader can receive a cartridge shield containing a cartridge therein, and when in the second configuration, if no cartridge shield is received, the cleaning assembly is configured to disinfect the cartridge loader.
G21F 5/015 - Transportable or portable shielded containers for storing radioactive sources, e.g. source carriers for irradiation unitsRadioisotope containers
6.
System and Method For Fractional Elution of Mother-Daughter Radionuclides
A method and a system for eluting a desired activity concentration of a daughter radionuclide-containing eluate obtained from a mixture of mother/daughter radionuclides is disclosed. The method comprises contacting separation particles with an aqueous solution containing a mixture of mother and daughter radionuclides wherein daughter radionuclides bind to separation particles and mother radionuclides does not. That contact is maintained for a time for unbound daughter radionuclide to bind to the separation particles. The unbound mother radionuclide is separated from the daughter radionuclide-bound separation particles using a washing solution. A first fractional amount of the bound daughter radionuclide is stripped from the separation particles using a volume of stripping solution so that an aqueous eluate solution having a desired daughter radionuclide activity is obtained. The remaining aqueous solution containing a second fractional amount of the desired daughter radionuclide still in the aqueous solution is retained.
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
7.
SYSTEM AND METHOD FOR FRACTIONAL ELUTION OF MOTHER-DAUGHTER RADIONUCLIDES
A method and a system for eluting a desired activity concentration of a daughter radionuclide-containing eluate obtained from a mixture of mother/daughter radionuclides is disclosed. The method comprises contacting separation particles with an aqueous solution containing a mixture of mother and daughter radionuclides wherein daughter radionuclides bind to separation particles and mother radionuclides does not. That contact is maintained for a time for unbound daughter radionuclide to bind to the separation particles. The unbound mother radionuclide is separated from the daughter radionuclide-bound separation particles using a washing solution. A first fractional amount of the bound daughter radionuclide is stripped from the separation particles using a volume of stripping solution so that an aqueous eluate solution having a desired daughter radionuclide activity is obtained. The remaining aqueous solution containing a second fractional amount of the desired daughter radionuclide still in the aqueous solution is retained.
C22B 3/24 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means by adsorption on solid substances, e.g. by extraction with solid resins
B01D 15/26 - Selective adsorption, e.g. chromatography characterised by the separation mechanism
B01J 20/286 - Phases chemically bonded to a substrate, e.g. to silica or to polymers
G21K 1/06 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating using diffraction, refraction, or reflection, e.g. monochromators
G21K 5/08 - Holders for targets or for objects to be irradiated
A converter for converting an electron beam into photons is provided. The converter can include a plurality of spherical beads made of high atomic number (high-Z material) disposed within a coolant fluid. The converter can include an inlet and an outlet for the coolant fluid. The coolant fluid can flow in a opposite direction as a direction of an electron beam.
G21K 1/06 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating using diffraction, refraction, or reflection, e.g. monochromators
10.
METHOD FOR STACKED ELUTION OF MOTHER-DAUGHTER RADIONUCLIDES
A method for enhancing radionuclide activity of a daughter radionuclide-containing eluate obtained from a mixture of mother/daughter radionuclides is disclosed. This method comprises i) contacting separation particles with an aqueous solution containing a mixture of mother and daughter radionuclides wherein daughter radionuclides bind to separation particles and mother radionuclides does not. That contact is maintained ii) for a time for unbound daughter radionuclide to bind to the separation particles. Unbound mother radionuclide is iii) separated from the daughter radionuclide-bound separation particles using a washing solution. Steps i) and ii) are repeated at least once iv). The bound daughter radionuclide is stripped v) from the separation particles using a volume of stripping solution less than that used if only steps i), ii), iii) and v) were used for each of the recited at least two separations to form an aqueous eluate having enhanced daughter radionuclide activity.
C01G 15/00 - Compounds of gallium, indium, or thallium
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
11.
METHOD FOR STACKED ELUTION OF MOTHER-DAUGHTER RADIONUCLIDES
A method for enhancing radionuclide activity of a daughter radionuclide-containing eluate obtained from a mixture of mother/daughter radionuclides is disclosed. This method comprises i) contacting separation particles with an aqueous solution containing a mixture of mother and daughter radionuclides wherein daughter radionuclides bind to separation particles and mother radionuclides does not. That contact is maintained ii) for a time for unbound daughter radionuclide to bind to the separation particles. Unbound mother radionuclide is iii) separated from the daughter radionuclide-bound separation particles using a washing solution. Steps i) and ii) are repeated at least once iv). The bound daughter radionuclide is stripped v) from the separation particles using a volume of stripping solution less than that used if only steps i), ii), iii) and v) were used for each of the recited at least two separations to form an aqueous eluate having enhanced daughter radionuclide activity.
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/286 - Phases chemically bonded to a substrate, e.g. to silica or to polymers
A multiple source container for radioactive material is provided. The multiple source container can include a cap attachable to a housing. The housing can include a plurality of source vials and a plurality of transfer vials. The cap and the housing can each be made from a radiation shielding material such that the source vials and the transfer vials can store radioactive material therein. The multiple source container can further include a plurality of ports, wherein a hole can be provided at a bottom of each of the plurality of source vials and each of the plurality of transfer vials, wherein the hole can each be coupled to one of the plurality of ports respective.
G21F 5/015 - Transportable or portable shielded containers for storing radioactive sources, e.g. source carriers for irradiation unitsRadioisotope containers
G21F 5/12 - Closures for containersSealing arrangements
A multiple source container for radioactive material is provided. The multiple source container can include a cap attachable to a housing. The housing can include a plurality of source vials and a plurality of transfer vials. The cap and the housing can each be made from a radiation shielding material such that the source vials and the transfer vials can store radioactive material therein. The multiple source container can further include a plurality of ports, wherein a hole can be provided at a bottom of each of the plurality of source vials and each of the plurality of transfer vials, wherein the hole can each be coupled to one of the plurality of ports respective.
G21F 5/015 - Transportable or portable shielded containers for storing radioactive sources, e.g. source carriers for irradiation unitsRadioisotope containers
A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe
B65D 51/16 - Closures not otherwise provided for with means for venting air or gas
B65D 71/00 - Bundles of articles held together by packaging elements for convenience of storage or transport, e.g. portable segregating carrier for plural receptacles such as beer cans or pop bottlesBales of material
B65D 77/22 - Packages formed by enclosing articles or materials in preformed containers, e.g. boxes, cartons, sacks or bags Details
G21F 5/02 - Transportable or portable shielded containers with provision for restricted exposure of a radiation source within the container
G21F 5/12 - Closures for containersSealing arrangements
A clean rinsing revering bypass rotary valve is provided. The valve can include a rotor and a stator. The stator can include one or more flow-through holes, each coupled to a fluid conduit in a valve housing. The rotor can include one or more rotor conduits. The rotor conduits can interact with the flow-through holes of the stator to create one or more configuration combos, each with a distinctive fluid flow path.
F16K 11/074 - Multiple-way valves, e.g. mixing valvesPipe fittings incorporating such valvesArrangement of valves and flow lines specially adapted for mixing fluid with all movable sealing faces moving as one unit comprising only sliding valves with pivoted closure members with flat sealing faces
F16K 27/04 - Construction of housingsUse of materials therefor of sliding valves
A clean rinsing revering bypass rotary valve is provided. The valve can include a rotor and a stator. The stator can include one or more flow-through holes, each coupled to a fluid conduit in a valve housing. The rotor can include one or more rotor conduits. The rotor conduits can interact with the flow-through holes of the stator to create one or more configuration combos, each with a distinctive fluid flow path.
F16K 31/05 - Operating meansReleasing devices electricOperating meansReleasing devices magnetic using a motor specially adapted for operating hand-operated valves or for combined motor and hand operation
F16K 11/07 - Multiple-way valves, e.g. mixing valvesPipe fittings incorporating such valvesArrangement of valves and flow lines specially adapted for mixing fluid with all movable sealing faces moving as one unit comprising only sliding valves with linearly sliding closure members with cylindrical slides
A fluid flow system configuration which simplifies the automation of fluid control, particularly for chemical processing systems where the minimization of fluid usage and processing speed are desired, particularly for the elution of radiopharmaceutical products. The fluid flow system comprises one or more input fluid containers for inputting fluid into the fluid flow system; a fluid flow control system coupled to the fluid flow containers, wherein the fluid flow control system controls and regulates fluid flowing through the fluid flow system; and one or more output fluid containers for receiving fluid outputted from the fluid flow control system. The fluid flow system integrates the use of single or multiple control reversing bypass valves as part of a fluid flow control system, whereby each reversing bypass valve can independently control flow direction forward, reverse, and/or bypass through the same flow path loop.
A fluid flow system configuration which simplifies the automation of fluid control, particularly for chemical processing systems where the minimization of fluid usage and processing speed are desired, particularly for the elution of radiopharmaceutical products. The fluid flow system comprises one or more input fluid containers for inputting fluid into the fluid flow system; a fluid flow control system coupled to the fluid flow containers, wherein the fluid flow control system controls and regulates fluid flowing through the fluid flow system; and one or more output fluid containers for receiving fluid outputted from the fluid flow control system. The fluid flow system integrates the use of single or multiple control reversing bypass valves as part of a fluid flow control system, whereby each reversing bypass valve can independently control flow direction forward, reverse, and/or bypass through the same flow path loop.
A converter for converting an electron beam into photons is provided. The converter can include a plurality of spherical beads made of high atomic number (high-Z material) disposed within a coolant fluid. The converter can include an inlet and an outlet for the coolant fluid. The coolant fluid can flow in a opposite direction as a direction of an electron beam.
A UV port disinfection system and method is disclosed. The UV port disinfection system can include a UV light source, a UV arm, and a UV arm pivoting axis, wherein the UV light source is connected to the UV arm, and wherein the UV arm is located on the UV arm pivoting axis and is rotatable on the axis to allow the UV arm to extend to one or more fluid input ports. Further, when the arm is over said fluid input port, said UV light source activates and emits UV light which disinfects said port. In a further embodiment, the UV port disinfection system can include a controller. A method for UV port disinfection is also disclosed.
A dual needle assembly comprising a housing comprising a first sterility filter, and a second sterility filter, a first needle for transporting a liquid comprising a first end coupled to the housing; and a second end extending from the housing, a second needle for transporting a stream of air comprising a third end coupled to the housing, and a fourth end extending from the housing. The first sterility filter is in-line with the first needle, such that the liquid transported via the first needle passes through the first sterility filter. The second sterility filter is in-line with the second needle, such that the stream of air transported via the second needle passes through the second sterility filter. The first sterility filter can be a fluid filter. The second sterility filter can be an air filter.
A fluid connector is provided. The fluid connector can include a first connector having a first passageway and a second passageway; and a second connector having a third passageway and a fourth passageway. The first connector can be attracted to the second connector through a magnetic force, thereby forming the fluid connector. Moreover, when the first connector abuts the second connector, the first passageway together with the third passageway can form a first fluid path, and the second passageway together with the fourth passageway can form a second fluid path that is different from the first fluid path.
A fluid connector is provided. The fluid connector can include a first connector having a first passageway and a second passageway; and a second connector having a third passageway and a fourth passageway. The first connector can be attracted to the second connector through a magnetic force, thereby forming the fluid connector. Moreover, when the first connector abuts the second connector, the first passageway together with the third passageway can form a first fluid path, and the second passageway together with the fourth passageway can form a second fluid path that is different from the first fluid path.
A novel cell for generating ozonated water, the cell comprises a nafion membrane separating a diamond coated anode, and a gold surfaced cathode enclosed within a cell housing with the catalyst side of the nafion membrane facing the cathode. The cell housing has a cathode housing portion and an anode housing portion separated by the membrane, each housing portion having ridges to enhance substantially even flow of fluid over the cathode and anode. The housing portions contain O-rings in grooves to prevent leaks, and alignment features to keep the electrodes aligned. The cathode and anode have an array of holes allowing fluid to penetrate to the surface of the niobium membrane. Input ports allow fluid to flow into the housing and over the anode and cathode and then out of the housing through outlet ports. The housing may also incorporate an integrated spectral photometer including a bubble trap.
A targeted radiopharmaceutical of chemical Formula I, below, is disclosed wherein Q+3 is a
A targeted radiopharmaceutical of chemical Formula I, below, is disclosed wherein Q+3 is a
trivalent radioactive isotope ion; M is a proton (H+), an ammonium ion or an alkali metal ion; “g” is a number that is 1 to about 12; the boxed mAb MNPR-101 represents the chemically-bonded humanized mAb MNPR-101; and Y− is an optional anion present in an amount needed to balance the ionic charge. A pharmaceutical composition that comprises a theranostic effective amount of a Formula I targeted radiopharmaceutical dissolved or dispersed in a pharmaceutically acceptable diluent is also disclosed, as are a method for treating and/or diagnosing a mammalian host having a disease, disorder or condition characterized by undesired angiogenesis, tumor growth and/or tumor metastasis. A targeted pro-radiopharmaceutical construct similar to that of Formula I but without the radioisotope (Formula III) is also contemplated.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
25.
Trivalent Radioisotope Bio-Targeted Radiopharmaceutical, Methods Of Preparation And Use
A targeted radiopharmaceutical comprising a targeting species chemically-bonded to a PCTA-chelated Q+3 trivalent radioactive ion of Formula I
A targeted radiopharmaceutical comprising a targeting species chemically-bonded to a PCTA-chelated Q+3 trivalent radioactive ion of Formula I
A targeted radiopharmaceutical comprising a targeting species chemically-bonded to a PCTA-chelated Q+3 trivalent radioactive ion of Formula I
is disclosed. Six of R1 through R7 are H and the seventh is a reacted functionality, Z, that forms the chemical bond with the targeting species, T. “g” is a number whose average value is 1 to about 12. X1, X2, and X3, are substituent groups that can coordinate to the Q+3 ion and/or help neutralize the ionic charge. Anion Y− is optionally present to balance the ionic charge. A pharmaceutical composition comprising a theranostic effective amount of a targeted radiopharmaceutical of Formula I in a pharmaceutically acceptable diluent is also contemplated, as are a method for treating and/or diagnosing a mammalian host having a disease, disorder or condition characterized by undesired angiogenesis, tumor growth and/or tumor metastasis.
A targeted radiopharmaceutical of chemical Formula I, below, is disclosed wherein Q+3 is a trivalent radioactive isotope ion; M is a proton (H+), an ammonium ion or an alkali metal ion; "g" is a number that is 1 to about 12; the boxed mAb MNPR- 101 represents the chemically-bonded humanized mAb MNPR-101; and Y- is an optional anion present in an amount needed to balance the ionic charge, A pharmaceutical composition that comprises a theranostic effective amount of a Formula I targeted radiopharmaceutical dissolved or dispersed in a pharmaceutically acceptable diluent is also disclosed, as are a method for treating and/or diagnosing a mammalian host having a disease, disorder or condition characterized by undesired angiogenesis, tumor growth and/or tumor metastasis. A targeted pro-radiopharmaceutical construct similar to that of Formula I but without the radioisotope (Formula III) is also contemplated.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
27.
TRIVALENT RADIOISOTOPE BIO-TARGETED RADIOPHARMACEUTICAL, METHODS OF PREPARATION AND USE
A targeted radiopharmaceutical comprising a targeting species chemically-bonded to a PCTA-chelated Q+3 trivalent radioactive ion of Formula I is disclosed. Six of R1through R7are H and the seventh is a reacted functionality, Z, that forms the chemical bond with the targeting species, T. "g" is a number whose average value is 1 to about 12. X1, X2, and X3, are substituent groups that can coordinate to the Q+3 ion and/or help neutralize the ionic charge. Anion Y- is optionally present to balance the ionic charge. A pharmaceutical composition comprising a theranostic effective amount of a targeted radiopharmaceutical of Formula I in a pharmaceutically acceptable diluent is also contemplated, as are a method for treating and/or diagnosing a mammalian host having a disease, disorder or condition characterized by undesired angiogenesis, tumor growth and/or tumor metastasis.
C07D 487/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains two hetero rings
A targeted radiopharmaceutical of chemical Formula I, below, is disclosed wherein Q+3 is a trivalent radioactive isotope ion; M is a proton (H+), an ammonium ion or an alkali metal ion; "g" is a number that is 1 to about 12; the boxed mAb MNPR- 101 represents the chemically-bonded humanized mAb MNPR-101; and Y- is an optional anion present in an amount needed to balance the ionic charge, A pharmaceutical composition that comprises a theranostic effective amount of a Formula I targeted radiopharmaceutical dissolved or dispersed in a pharmaceutically acceptable diluent is also disclosed, as are a method for treating and/or diagnosing a mammalian host having a disease, disorder or condition characterized by undesired angiogenesis, tumor growth and/or tumor metastasis. A targeted pro-radiopharmaceutical construct similar to that of Formula I but without the radioisotope (Formula III) is also contemplated.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A system and method for producing radioisotopes such as molybdenum-99. The system comprises a first accelerator, a second accelerator, a first beamline, a second beamline, and a target. Using a pair of accelerators, beamlines are preferably fired at a target from opposite directions, thereby irradiating the target from both sides. The system can further comprise a target cooling system utilizing gaseous helium, a modular local target shielding comprised of boxes of either metal shot with liquid coolant or steel with concrete, and a hot cell for loading and unloading target disks.
G21G 1/10 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators by bombardment with electrically-charged particles
G21G 1/12 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators by electromagnetic irradiation, e.g. with gamma or X-rays
G21K 5/04 - Irradiation devices with beam-forming means
G21K 5/08 - Holders for targets or for objects to be irradiated
H05H 6/00 - Targets for producing nuclear reactions
30.
Systems and methods for ozone water generation cell with integrated detection
A novel cell for generating ozonated water including an integrated ozone concentration detector. The cell comprises a nafion membrane separating a diamond coated anode, and a gold surfaced cathode enclosed within a cell housing with the catalyst side of the nafion membrane facing the cathode. The cell housing has a cathode housing portion and an anode housing portion separated by the membrane. The cathode and anode have an array of holes allowing fluid to penetrate to the surface of the niobium membrane. Ozonated water from the anode is channeled to a spectrophotometer integrated within the housing. The spectrophotometer creates a signal representative of the ozone concentration in the ozonated water which is utilized by control circuitry in a closed loop to maintain a stable target concentration. A bubble trap may be integrated within the housing through which the ozonated water passes before entering the spectrophotometer to remove bubbles form the ozonated water. Input ports allow fluid to flow into the housing and over the anode and cathode and then out of the housing through outlet ports.
A novel system for generating ozonated water, for example, for sterilization of medical equipment. The system comprises an ozone generating cell including a nafion membrane separating an anode, and a cathode enclosed within a cell housing. The cell housing has a cathode housing portion and an anode housing portion separated by the membrane. The housing also incorporates an integrated spectrophotometer including a bubble trap. The system includes a hydrogen water reservoir for receiving water from the cathode and an ozone water reservoir for receiving generated ozonated water from the anode. Control circuitry controls a set of pumps, and controls ozone generation in a closed loop using the spectrophotometer to provide a selected ozone concentration in the ozonated water from the anode. An output port coupled to the ozone water reservoir allows ozonated water to flow out of the system for external use.
A novel cell for generating ozonated water, the cell comprises a nafion membrane separating a diamond coated anode, and a gold surfaced cathode enclosed within a cell housing with the catalyst side of the nafion membrane facing the cathode. The cell housing has a cathode housing portion and an anode housing portion separated by the membrane, each housing portion having ridges to enhance substantially even flow of fluid over the cathode and anode. The housing portions contain O-rings in grooves to prevent leaks, and alignment features to keep the electrodes aligned. The cathode and anode have an array of holes allowing fluid to penetrate to the surface of the niobium membrane. Input ports allow fluid to flow into the housing and over the anode and cathode and then out of the housing through outlet ports. The housing may also incorporate an integrated spectral photometer including a bubble trap.
A novel system for generating ozonated water, for example, for sterilization of medical equipment. The system comprises an ozone generating cell including a nafion membrane separating an anode, and a cathode enclosed within a cell housing. The cell housing has a cathode housing portion and an anode housing portion separated by the membrane. The housing also incorporates an integrated spectrophotometer including a bubble trap. The system includes a hydrogen water reservoir for receiving water from the cathode and an ozone water reservoir for receiving generated ozonated water from the anode. Control circuitry controls a set of pumps, and controls ozone generation in a closed loop using the spectrophotometer to provide a selected ozone concentration in the ozonated water from the anode. An output port coupled to the ozone water reservoir allows ozonated water to flow out of the system for external use.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemical reagents for medical, therapeutic and
pharmaceutical purposes; medical diagnostic reagents. Scientific apparatus and instruments for separating chemical
isotopes. Medical apparatus, namely, a unit for chemical isotope
separation.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
(1) Chemical reagents for use in the manufacture of pharmaceutical preparations
(2) Diagnostic reagents for medical laboratory and medical diagnostic use; medical diagnostic reagents; isotopes for medical, therapeutic and diagnostic purposes; isotopes for use in pharmaceutical preparations
(3) Scientific apparatus, namely, a system comprised of valves, controllers, filters, syringes, tubing, and shielding for separating chemical isotopes
(4) Medical apparatus, namely, a system comprised of valves, controllers, filters, syringes, tubing, and shielding for chemical isotope separation
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemical reagents for medical, therapeutic and pharmaceutical purposes; medical diagnostic reagents; isotopes for medical, therapeutic and diagnostic purposes; isotopes for use in pharmaceutical preparations. Scientific apparatus and instruments for separating chemical isotopes. Medical apparatus, namely, a unit for chemical isotope.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemical reagents for use in the manufacture of pharmaceutical preparations; isotopes for use in the manufacture of pharmaceutical preparations Chemical reagents for medical and medical therapeutic purposes; medical diagnostic reagents; isotopes for medical, medical therapeutic and medical diagnostic purposes Scientific apparatus, namely, a system comprised of [ valves, controllers, filters, ] syringes, [ tubing, ] and shielding for [ separating ] chemical isotopes Medical apparatus, namely, a system comprised of [ valves, controllers, filters, ] syringes, [ tubing, ] and shielding for chemical isotope [ separation for medical diagnostic imaging ]
